Company: GRCE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001140361-25-041804
Chunk: 40

Company: Grace Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Item 8
Chunk 40
---
, after deducting fees and expenses.

  35
  

   2023 Private Placement

In
September 2023, we entered into a securities purchase agreement (the “2023
Purchase Agreement”) with certain institutional and accredited investors in
connection with a private placement offering of our securities (the “2023
Private Placement”). Pursuant to the 2023 Purchase Agreement, we sold 1,951,371
Common Shares, at a purchase price of $1.848 per Common Share and pre-funded
warrants (the “2023 Pre-Funded Warrants”) to purchase up to 2,106,853 Common
Shares at a purchase price equal to the purchase price per Common Share less
$0.0001. Each 2023 Pre-Funded Warrant is exercisable for one Common Share at an
exercise price of $0.0001 per Common Share, is immediately exercisable, and
will expire once exercised in full. Pursuant to the 2023 Purchase Agreement, we
also issued to such institutional and accredited investors common warrants (the
“2023 Common Warrants”, and together with the 2023 Pre-Funded Warrants, the
“Warrants”) to purchase Common Shares, exercisable for an aggregate of
2,536,391 Common Shares. Under the terms of the 2023 Purchase Agreement, for
each Common Share and each 2023 Pre-Funded Warrant issued in the 2023 Private
Placement, an accompanying five-eighths (0.625) of a 2023 Common Warrant was
issued to the purchaser thereof. Each whole 2023 Common Warrant is exercisable
for one Common Share at an exercise price of $3.003 per Common Share, is
immediately exercisable, and will expire on the earlier of (i) the 60th day
after the date of the acceptance by the FDA of an NDA for our product candidate
GTx-104 or (ii) five years from the date of issuance. The 2023 Private
Placement closed on September 25, 2023. The net proceeds to us from the 2023
Private Placement were $7,338, after deducting fees and expenses. In October
2025, the Company received $4,000 in gross proceeds from exercises of 1,345,464 2023 Common
Warrants that were issued in the 2023
Private Placement. for
1,345,